All questions are shown as received by the Trust.
Q1. How many patients have you treated with Pembrolizumab in the three months from May 2023 to July 2023 for:
• Melanoma – any stage
• Stage IIb/IIc Melanoma
• Stage III Melanoma
• Metastatic Melanoma
Q2. How many Stage IIb/IIc melanoma patients were on a “Watch and Wait” strategy in the three months from May 2023 to July 2023? These would be patients where a decision has been made to wait before commencing any treatment.